Beigene (NASDAQ:ONC) Issues Earnings Results

Beigene (NASDAQ:ONC - Get Free Report) issued its earnings results on Wednesday. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93, Zacks reports. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Beigene updated its FY 2025 guidance to EPS.

Beigene Trading Down 1.7%

Beigene stock traded down $3.95 during midday trading on Friday, reaching $231.99. 375,689 shares of the stock traded hands, compared to its average volume of 482,095. The firm has a market capitalization of $22.95 billion, a price-to-earnings ratio of -28.15, a PEG ratio of 7.73 and a beta of 0.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The business has a 50-day simple moving average of $245.87. Beigene has a 12-month low of $141.31 and a 12-month high of $287.88.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada reduced their target price on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research report on Thursday. JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th. Guggenheim raised their price objective on Beigene from $348.00 to $350.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Macquarie increased their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $319.00.

Insiders Place Their Bets

In related news, insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $242.66, for a total transaction of $10,133,481.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $260.00, for a total value of $190,535,020.00. Following the sale, the director now owns 730,642 shares in the company, valued at approximately $189,966,920. This trade represents a 50.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,146,048 shares of company stock worth $295,198,300 over the last three months. Company insiders own 6.62% of the company's stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.